TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient…

TRUQAP won FDA approval for PTEN-deficient metastatic prostate cancer with 19% risk reduction—first targeted therapy available. Companion diagnostic approval marks precision medicine maturity: genomic testing bundled with therapy now reshapes oncology development and reimbursement.